Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)-Reference-Cited by-同舟云学术

Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)

Published:2022-09 Issue: Volume:134 Page:155246
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Valenzuela-Vallejo Laura,Mantzoros Christos S.

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference92 articles.

1. Clinical practice guidelines for the management of non-alcoholic fatty liver disease;EASL-EASD-EASO;J Hepatol,2016

2. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

3. Nonalcoholic steatohepatitis: a review;Sheka;JAMA,2020

4. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH;Loomba;Hepatology,2019

5. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management;Metabolism;2024-08

2. Associations of activity, sedentary and sleep behaviors with prevalent steatotic liver disease in middle-aged and older adults: the ELSA-Brasil study;Journal of Activity, Sedentary and Sleep Behaviors;2024-07-03

3. A high reticulocyte count is a risk factor for the onset of metabolic dysfunction-associated steatotic liver disease: Cross-sectional and prospective studies of data of 310,091 individuals from the UK Biobank;Frontiers in Pharmacology;2024-07-01

4. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges;Metabolism;2024-05

5. Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities;World Journal of Gastrointestinal Pathophysiology;2024-04-22